Novel Scorpion Toxin ω-Buthitoxin-Hf1a Selectively Inhibits Calcium Influx via CaV3.3 and CaV3.2 and Alleviates Allodynia in a Mouse Model of Acute Postsurgical Pain

Dan Wang,Volker Herzig,Zoltan Dekan,K. Johan Rosengren,Colton D. Payne,Md. Mahadhi Hasan,Jiajie Zhuang,Emmanuel Bourinet,Lotten Ragnarsson,Paul F. Alewood,Richard J. Lewis

DOI: https://doi.org/10.3390/ijms25094745

IF: 5.6

2024-04-27

International Journal of Molecular Sciences

Abstract:Venom peptides have evolved to target a wide range of membrane proteins through diverse mechanisms of action and structures, providing promising therapeutic leads for diseases, including pain, epilepsy, and cancer, as well as unique probes of ion channel structure-function. In this work, a high-throughput FLIPR window current screening assay on T-type CaV3.2 guided the isolation of a novel peptide named ω-Buthitoxin-Hf1a from scorpion Hottentotta franzwerneri crude venom. At only 10 amino acid residues with one disulfide bond, it is not only the smallest venom peptide known to target T-type CaVs but also the smallest structured scorpion venom peptide yet discovered. Synthetic Hf1a peptides were prepared with C-terminal amidation (Hf1a-NH2) or a free C-terminus (Hf1a-OH). Electrophysiological characterization revealed Hf1a-NH2 to be a concentration-dependent partial inhibitor of CaV3.2 (IC50 = 1.18 μM) and CaV3.3 (IC50 = 0.49 μM) depolarized currents but was ineffective at CaV3.1. Hf1a-OH did not show activity against any of the three T-type subtypes. Additionally, neither form showed activity against N-type CaV2.2 or L-type calcium channels. The three-dimensional structure of Hf1a-NH2 was determined using NMR spectroscopy and used in docking studies to predict its binding site at CaV3.2 and CaV3.3. As both CaV3.2 and CaV3.3 have been implicated in peripheral pain signaling, the analgesic potential of Hf1a-NH2 was explored in vivo in a mouse model of incision-induced acute post-surgical pain. Consistent with this role, Hf1a-NH2 produced antiallodynia in both mechanical and thermal pain.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a new analgesic drug, especially for the treatment of acute postoperative pain. Researchers isolated a new peptide toxin, ω - Buthitoxin - Hf1a, from scorpion venom. This toxin can selectively inhibit T - type calcium channels (CaV3.2 and CaV3.3), thereby reducing mechanical and thermal hyperalgesia in mouse models. Specifically, the main objectives of the paper include:

1. **Identification of new peptide toxins**: A new peptide toxin, ω - Buthitoxin - Hf1a, was isolated from the crude venom of the scorpion Hottentotta franzwerneri through a high - throughput FLIPR window current screening test.

2. **Structure and function analysis**: Determine the amino acid sequence of ω - Buthitoxin - Hf1a, analyze its three - dimensional structure by NMR spectroscopy, and further study its binding mode with T - type calcium channels through molecular docking.

3. **Electrophysiological characteristics**: Through electrophysiological experiments, evaluate the effects of ω - Buthitoxin - Hf1a on different subtypes of T - type calcium channels (CaV3.1, CaV3.2, and CaV3.3) as well as high - voltage - activated (HVA) N - type (CaV2.2) and L - type calcium channels.

4. **In vivo analgesic effect**: In a mouse model of acute postoperative pain, evaluate the analgesic effect of ω - Buthitoxin - Hf1a, especially its relieving effect on mechanical and thermal hyperalgesia.

In summary, this paper aims to provide a scientific basis for the potential application of the new peptide toxin ω - Buthitoxin - Hf1a in the treatment of acute postoperative pain through discovery and characterization.